Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in treating and managing this disease, consequently, new therapeutic strategies must be developed. Crossing the blood-brain barrier (BBB) is another challenge for most drug vectors and therapy medications. Filamentous bacteriophage can enter the brain across the BBB. Compared to traditional drug vectors, phage-based drugs offer thermodynamic stability, biocompatibility, homogeneity, high carrying capacity, self-assembly, scalability, and low toxicity. Tumor-targeting peptides from phage library and phages displaying targeting peptides are ideal drug delivery agents. This review summarized recent studies on phage-based glioma therapy and shed light on the developing therapeutics phage in the personalized treatment of glioma.
CITATION STYLE
Wang, Y., Sheng, J., Chai, J., Zhu, C., Li, X., Yang, W., … Ge, T. (2021, September 10). Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2021.729336
Mendeley helps you to discover research relevant for your work.